Alkermes plc - Ordinary Shares (ALKS) News

Alkermes plc - Ordinary Shares (ALKS): $24.17

-0.07 (-0.29%)

POWR Rating

Component Grades













Filter ALKS News Items

ALKS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ALKS News Highlights

  • 500 - Internal server error
  • Over the past 16 days, the trend for ALKS's stories per day has been choppy and unclear. It has oscillated between 1 and 17.
  • The most mentioned tickers in articles about ALKS are AMD, BIIB and CRM.

Latest ALKS News From Around the Web

Below are the latest news stories about Alkermes plc that investors may wish to consider to help them evaluate ALKS as an investment opportunity.

Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs

Biogen (NASDAQ: BIIB) stock rocketed to a six-year high earlier this week on news that its therapy, aducanumab, was the first Alzheimer's drug approved in nearly 20 years by the U.S. Food and Drug Administration (FDA). This is a huge deal, not only for Alzheimer's patients, but for Biogen and its shareholders. There are two other biotech stocks, however, whose recent breakthroughs could drive the profits for years to come, and they are still priced modestly -- for now.

Yahoo | June 13, 2021

Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting

- Updated Data From ARTISTRY Clinical Program Highlight Anti-Tumor Activity as Monotherapy and in Combination With Pembrolizumab - - Data Support Advancement of Regulatory Strategy in Cancers With High Unmet Need - - Company to Host Investor Webcast Today at 4:00 p.m. ET -

BioSpace | June 3, 2021

Alkermes to Take Part in the Goldman Sachs Annual Global Healthcare Conference

Alkermes plc announced that management will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 10:30 a.m. ET.

BioSpace | June 2, 2021

Biotech Stock Roundup: MRNA COVID-19 Vaccine Update, Drug Approvals for ALKS, MYOV & More

The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Alkermes (ALKS), among others.

Yahoo | June 2, 2021

Alkermes' (ALKS) Schizophrenia, Bipolar I Disorder Drug Approved

The FDA approves Alkermes' (ALKS) Lybalvi for the treatment of adults with schizophrenia or bipolar I disorder. Shares up

Yahoo | June 2, 2021

Thinking about trading options or stock in Alkermes, GameStop, Nio, Advanced Micro Devices, or Salesforce?

NEW YORK , June 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALKS, GME, NIO, AMD, and CRM. Full story available on

Benzinga | June 1, 2021

Alkermes stock halted for news pending

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit or the quote page for more information about this breaking news.

MarketWatch | June 1, 2021

Alkermes shares rise 7% as FDA approves antipsychotic Lyvalbi

No summary available.

Seeking Alpha | June 1, 2021

Alkermes schizophrenia drug gets U.S. FDA nod

Alkermes Plc said on Tuesday the U.S. Food and Drug Administration (FDA) approved its drug Lybalvi to treat schizophrenia and bipolar I disorder. The company expects to commercially launch the drug in the fourth quarter. (Reporting by Dania Nadeem in Bengaluru; Editing by Aditya Soni)

Financial Post | June 1, 2021

Alkermes Announces FDA Approval of LYBALVI for the Treatment of Schizophrenia and Bipolar I Disorder

-- New Oral Medication Offers Established Antipsychotic Efficacy of Olanzapine With Less Weight Gain -- -- Commercial Launch Planned for Fourth Quarter 2021 -- -- Company to Host Investor Conferen

FinanzNachrichten | June 1, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6289 seconds.